INTERNATIONAL STEM CELL CORPORATION (OTCMKTS:ISCO) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k
-
0

INTERNATIONAL STEM CELL CORPORATION (OTCMKTS:ISCO) Files An 8-K Submission of Matters to a Vote of Security Holders

ITEM 5.07 Submission of Matters to a Vote of Security Holders

The Company held its Annual Meeting of Stockholders on May 31,
2017. The stockholders considered three proposals, each of which
is described in more detail in the Companys definitive proxy
statement dated April 28, 2017.

Proposal 1:

Election of five directors to hold office until the 2018
Annual Meeting:

A.

Directors elected by holders of Series D Preferred Stock.

FOR

WITHHELD

Andrey Semechkin

2,457,142

Russell Kern

2,457,142

B.

Directors elected by holders of all shares of stock.

FOR

WITHHELD

Donald A. Wright

4,808,743

53,073

Paul V. Maier

4,809,136

52,680

Charles J. Casamento

4,809,094

52,722

Broker Non-Votes: 1,428,637

All of the foregoing candidates were elected.

Proposal 2:

Ratification of the selection of Mayer Hoffman McCann,
P.C., as the Companys independent public accountants for
the Companys fiscal year ending December 31, 2017 (shares
of common stock and all classes of preferred stock voting
together):

FOR

AGAINST

ABSTAIN

5,986,978

266,281

37,194

Broker Non-Votes: none

The foregoing proposal was approved.

Proposal 3:

Approval, on an advisory basis, of the compensation of
the Companys named executive officers as disclosed in the
proxy statement (shares of common stock and all classes
of preferred stock voting together):

FOR

AGAINST

ABSTAIN

4,765,631

78,081

18,104

Broker Non-Votes: 1,428,637

The foregoing proposal was approved.


About INTERNATIONAL STEM CELL CORPORATION (OTCMKTS:ISCO)

International Stem Cell Corporation (ISCO) is a biotechnology company. The Company is focused on therapeutic and biomedical product development. The Company’s segments include Therapeutic Market, Cosmetic Market and Biomedical Market. The Company’s subsidiaries include International Stem Cell Corporation, a research and development company, for the Therapeutic Market for clinical applications of human parthenogenetic stem cells (hpSCs) for the treatment of various diseases, such as Parkinson’s disease, liver diseases and corneal blindness; Cyto Therapeutics, PTY LTD, a research and development company, for the Therapeutic Market; Lifeline Skin Care, Inc. for the Cosmetic Market, which develops, manufactures and markets a category of cosmetic skin care products based on biotechnology with human stem cells, and Lifeline Cell Technology, LLC for the Biomedical Market, which develops, manufactures and commercializes primary human cell research products.